Supplementation with nicotinamide adenine dinucleotide (NAD⁺) precursors including dietary nicotinamide has been found to boost tissue NAD⁺ levels and ameliorate oxidative stress-induced damage that contributes to ageing and ageing-related diseases. The association between dietary NAD⁺ precursors and patient-reported health-related outcomes in cancer survivors has not been investigated. This study aimed at determining associations of dietary nicotinamide intake with different patient-reported outcomes and with hand-drip strength in colorectal cancer survivors, 2 to 10 years post-diagnosis. A total of 145 eligible participants were recruited into this cross-sectional study. Dietary nicotinamide intake level was calculated based on data from 7-day food diaries. Fatigue was assessed with the Checklist Individual Strength (CIS), subscale of EORTC and anxiety and depression were assessed with Hospital Anxiety and Depression Scale (HADS). Maximum isometric handgrip strength was measured by hand dynamometer. Cognitive and emotional functioning were measured by EORTC. Oxidative stress marker serum protein carbonyl contents and serum NAD⁺ levels were measured. Serum multiple cytokines IL-6, IL-4,IL-1β, THFα and IL-10 were determined by LUMINEX. A hierarchical linear regression model with confounder adjustment was performed to analyze the association of nicotinamide intake, serum protein carbonyl contents and NAD⁺ levels with patient-reported outcomes and hand-drip strength. The median values of daily nicotinamide intake for male and female participants were 19.1 and 14.4 mg, respectively. Daily dietary nicotinamide intake was associated with a lower level of fatigue (β: -14.85 [-28.14, -1.56]) and a lower level of anxiety and depression (β: -4.69 [-8.55, -0.83]). Significant dose-dependent associations were found in emotional functioning, fatigue and depression. To conclude, our findings suggested that higher dietary NAD⁺ precursor nicotinamide intake was cross-sectionally associated with less patient-reported outcomes in CRC survivors.